Immunome’s investigational oral therapy has slashed the risk of disease progression or death by 84% for patients with desmoid ...

The UK Medicines and Healthcare products Regulatory Agency (MHRA) has approved Ezmekly (mirdametinib) for the treatment of ...

An end-of-the-year slowdown has not been witnessed by the biopharma industry yet, and certainly not in the biotech deals ...

Europe's universities and research institutes are particularly strong in biotech and pharmaceutical startups. A report from Dealroom shows that since 2022 there have been 244 academic spinouts in ...

By Annette Bakker The tragedy of rare disease is not only measured in lives lost—it’s also measured in lives that could have been saved, if only abandoned discoveries had been given another chance.

Craig Crews, center, prepares to cut the ceremonial ribbon in front of Halda Therapeutics’ new home in Winchester Works in 2021. PHOTOS MICHELLE TUCCITTO SULLO Johnson & Johnson announced Monday ...

Merck & Co., Inc. (NYSE:MRK) is a global pharmaceutical company recogni⁠zed for its strong onco⁠l‌ogy lineup, led by‍ its fl⁠agsh⁠ip drug⁠ Keytruda, the top-selling medicin‌e in the w‌orld. The ...

Raveena obtained her bachelor's degree in biochemistry from the University of Leeds, UK. She has worked in the biopharma industry for more than 15 years, focusing on dealmaking, partnering and ...

SpringWorks immediately adds revenue and accelerates mid- to long-term growth for Merck KGaA, Darmstadt, Germany’s Healthcare business sector. Acquisition marks the formation of a rare tumor business ...

We recently published a list of the 20 Best Dividend Growth Stocks with High Yields. In this article, we are going to take a look at where Merck & Co., Inc. (NYSE:MRK) stands against other best ...

Merck KGaA struck a $3.9 billion deal for SpringWorks Therapeutics. Novartis plans to acquire Regulus Therapeutics for $800 million upfront and up to $1.7 billion overall. Biohaven signed a $600 ...